Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles for the RFPs are very
Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As a marvelous way to end
Dear All, Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two funding calls during 2026 (April
Dear All, Regular readers will be aware of the global conversation now happening around the threat arising from the potential to create viable organisms that
Dear All, In a paper that is clearly a labor of love (1,032 references!), Mark Butler and Robert Capon have summarized the history of 217
Dear All, Our colleagues in Europe have been busy! Along with yesterday’s announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe
Dear All, There are more details yet to come, but the EU Council (“the Council”) and the EU Parliament (EP) yesterday announced an agreement on
Note: As always, please use the copy of the newsletter posted at https://amr.solutions/ if you have trouble with links in this newsletter. Dear All, As I
Dear All, The 8 Dec 2025 newsletter entitled “Phage therapy: Regulatory perspectives from TATFAR” generated a fair bit of commentary! I’ve now added several post-newsletter
Dear All, Integrating perspectives from EC HERA, EMA, Health Canada, Norway, UK MHRA, US FDA, and US NIH, the Transatlantic Task Force on AMR (TATFAR)’s